How could greater flexibility play a role?

HTAs should be a flexible process used collaboratively.  The use of HTA to make reimbursement decisions should have as its key objective to improve health outcomes for patients through the rapid uptake of beneficial health innovations and technologies, without losing sight of social values.  A proper use of clinical and/or cost-effectiveness assessment of therapies should be aimed at increasing the understanding of its different benefits, value to patients and of public health and healthcare system impact.